The GROWTH Study, Glycemia Range and Offspring Weight and adiposity in response To Human milk

生长研究、血糖范围以及后代体重和肥胖对母乳的反应

• 批准号: 10595445
• 负责人: Brigid Ellen Gregg
• 金额: $ 200.79万
• 依托单位: LURIE CHILDREN'S HOSPITAL OF CHICAGO
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-04-01 至 2028-01-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10595445
• 关键词: 2 year old; Accounting; Address; Adipocytes; Anabolism; Ancillary Study; Beta Cell; Body Composition; Body fat; Body mass index; Breast Epithelial Cells; Breast Feeding; Categories; Cells; Child; Childhood; Development; Diet; Dissection; Enrollment; Environment; Epithelial Cells; Exposure to; Fatty Acids; Follow-Up Studies; Food; Functional disorder; Funding; Gene Expression; Gene Expression Profile; Gestational Diabetes; Glucose; Glucose Metabolism Disorders; Goals; Growth; Health; Human; Human Milk; Hyperglycemia; Hypertrophy; Infant; Insulin Resistance; Intervention; Knowledge; Lactation; Length; Linoleic Acids; Linolenic Acids; Lipids; Mammary gland; Measures; Metabolic; Metabolic Diseases; Metabolism; Milk; Modeling; Mothers; National Institute of Child Health and Human Development; Nutrient; Obesity; Outcome; Palmitic Acids; Pathologic; Pathway interactions; Phenotype; Postpartum Period; Predisposition; Pregnancy; Public Health; Regulation; Reproducibility; Research; Risk; Risk Reduction; Sampling; Scientist; Shapes; Testing; Time; Translational Research; United States National Institutes of Health; Validation; Variant; Weight; Woman; adipocyte differentiation; adverse pregnancy outcome; cardiometabolic risk; cohort; early childhood; experience; high body mass index; improved; in utero; in vitro testing; infant adiposity; inter-individual variation; lactation period; lactogenesis; lipid biosynthesis; mammary gland development; maternal condition; maternal diabetes; maternal hyperglycemia; maternal obesity; metabolic phenotype; mother nutrition; novel; nutrition; obesity in children; offspring; post pregnancy; prenatal exposure; prospective; response; screening; transcriptomics; translational study

ABSTRACT Maternal metabolism during pregnancy is a key contributor to developmental origins of metabolic disease. Offspring exposed to maternal hyperglycemia and obesity have increased rates of obesity and disordered glucose metabolism. The lactation period is also a critical window for programming. Lactogenesis initiates in the second half of gestation, thus human milk (HM) biosynthesis is susceptible maternal metabolism. Interindividual variation in HM nutrients reveals the influence of maternal metabolism on milk biosynthesis. A knowledge gap exists as to whether HM composition alters developmental pathways of offspring programmed in utero. Maternal metabolic states including gestational diabietes (GDM) and obesity alter HM nutrient profiles, including milk fatty acids (FA). Our studies identified altered HM linoleic acid and dihomo-gamma-linolenic acid (DGLA) in conditions of maternal diabetes, hyperglycemia, and obesity, as well as HM palmitic acid and DGLA associations with infant growth. However, any impact of maternal metabolism across the entire range of glycemia on both HM composition and offspring programming has not been evaluated in context of detailed profiling of in utero exposures. Our goal is to understand how HM susceptibility to maternal metabolism impacts offspring metabolism, identifying interventions to mitigate adverse developmental programming. This proposal’s objective is to determine the impact of maternal glycemia in pregnancy on HM composition and effects of HM nutrients on offspring adiposity. Translational science approaches will determine how maternal glycemia alters mammary gland epithelial cell gene expression and how HM lipids across the range of maternal glycemia regulate infant adipoctyes. Our overarching hypothesis is that maternal glycemia in normal and pathologic ranges impacts HM composition, which in turn influences offspring metabolic programming as reflected by early childhood adiposity. Capitalizing on the detailed metabolic phenotyping of the GO MOMs cohort, we will conduct prospective HM profiling at 1, 2 and 6 months post-partum in a cohort of 450 women to associate maternal glycemia during and after pregnancy, focusing on HM lipids known to regulate offspring adiposity (Aim 1). Mammary epithelial cells shed in expressed HM will be evaluated using transcriptomics (SubAim 1). For reproducibility, HM lipids will be compared to a separate validation cohort enrolling women with GDM. We will measure offspring body composition to discern adiposity at months 1, 2, and 6 and 2 years, accounting for childhood diet (Aim 2). A human infant preadipocyte strain will be exposed to HM lipids collected and grouped by quartiles of maternal glycemia to determine mechanisms altering infant adipocyte development (Aim 3). Completing the aims will define HM composition in a pregnancy cohort with comprehensive metabolic profiling throughout pregnancy and lactation across the range of glycemia and BMI. Offspring growth and translational studies will advance understanding of how lactation exposures modify in utero programming. This will further the field by revealing interventions to reduce risk of adverse offspring metabolic health.

摘要